Abstract
According to classical thinking about Parkinsons disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (l-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinsons disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinsons disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
Keywords: 7-Nitroindazole, Motor behaviour, Nitric oxide synthase inhibitor, Dopamine, Mice, L-DOPA, Dyskinesia, Parkinson's disease, Abnormal involuntary movements
Current Pharmaceutical Design
Title: Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment
Volume: 17 Issue: 5
Author(s): Elaine Del-Bel, Fernando Eduardo Padovan-Neto, Rita Raisman-Vozari and Marcio Lazzarini
Affiliation:
Keywords: 7-Nitroindazole, Motor behaviour, Nitric oxide synthase inhibitor, Dopamine, Mice, L-DOPA, Dyskinesia, Parkinson's disease, Abnormal involuntary movements
Abstract: According to classical thinking about Parkinsons disease, loss of dopaminergic input from the substantia nigra pars compacta leads to overactivity and underactivity of the indirect and direct output pathways, respectively, in the basal ganglia. Administration of the dopamine precursor L-DOPA (l-3, 4-dihydroxyphenylalanine) is proposed to induce changes in the opposite directions. L-DOPA is the most used drug to treat Parkinsons disease symptoms. After repeated treatment with this compound, however, disabling secondary effects such as the abnormal involuntary movements usually appear. Nitric oxide is a free radical that can also acts as an atypical neurotransmitter and influences dopamine-mediated neurotransmission. In this paper we will briefly review the role of nitric oxide on motor control and in Parkinsons disease, particularly a possible role of nitric oxide in L-DOPA induced dyskinesia in rodents. Recent results show that nitric oxide synthase inhibition reduces L-DOPA-induced dyskinesia in rats and mice. The effect is dose-dependent, does not suffer tolerance nor interferes with L-DOPA positive motor effects. These preclinical findings suggest that nitric oxide is a promising therapeutic target for the reduction of L-DOPA-induced dyskinesia.
Export Options
About this article
Cite this article as:
Del-Bel Elaine, Eduardo Padovan-Neto Fernando, Raisman-Vozari Rita and Lazzarini Marcio, Role of Nitric Oxide in Motor Control: Implications for Parkinsons Disease Pathophysiology and Treatment, Current Pharmaceutical Design 2011; 17 (5) . https://dx.doi.org/10.2174/138161211795164176
DOI https://dx.doi.org/10.2174/138161211795164176 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms
Current Drug Therapy Road to Future: iPSC Clinical Application in Parkinson’s Disease Treatment
Current Molecular Medicine Urine Cells-derived iPSCs: An Upcoming Frontier in Regenerative Medicine
Current Medicinal Chemistry Catechol-O-Methyltransferase (COMT)-Mediated Methylation Metabolism of Endogenous Bioactive Catechols and Modulation by Endobiotics and Xenobiotics: Importance in Pathophysiology and Pathogenesis
Current Drug Metabolism Overview of Tyrosine Hydroxylase in Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects
Current Medicinal Chemistry Stress Echocardiography
Current Pharmaceutical Design Mitochondrial Tolerance to Drugs and Toxic Agents in Ageing and Disease
Current Drug Targets Deprescribing Antipsychotic Medications in Psychotic Disorders: How and Why?
Current Psychiatry Reviews Neurobiological Basis of Dyskinetic Effects Induced by Antipsychotics: the Contribution of Animal Models
Current Medicinal Chemistry Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Memantine and Kynurenic Acid: Current Neuropharmacological Aspects
Current Neuropharmacology Neuroprotection by NMDA Receptor Antagonists in a Variety of Neuropathologies
Current Drug Targets Novel Therapeutic Effects of the Anti-Convulsant, Zonisamide, on Parkinsons Disease
Current Pharmaceutical Design Differences in Medication Adherence, Satisfaction and Clinical Symptoms in Schizophrenic outpatients Taking Different Antipsychotic Regimens
Current Drug Safety The Use of Bifunctional NOP/Mu and NOP Receptor Selective Compounds for the Treatment of Pain, Drug Abuse, and Psychiatric Disorders
Current Pharmaceutical Design Mechanisms of Action of Antipsychotic Drugs of Different Classes, Refractoriness to Therapeutic Effects of Classical Neuroleptics, and Individual Variation in Sensitivity to their Actions: PART II
Current Neuropharmacology Prime Time for G-Protein-Coupled Receptor Heteromers as Therapeutic Targets for CNS disorders: The Dopamine D1-D3 Receptor Heteromer
CNS & Neurological Disorders - Drug Targets Molecular Recognisation of 3a, 4-Dihydro-3-H-Indeno [1, 2-C] Pyrazole-2- Carboxamide/Carbothioamide Anticonvulsant Analogues Towards GABA-Aminotransferase- An in Silico Approach
Central Nervous System Agents in Medicinal Chemistry